ProQR Therapeutics (NASDAQ: PRQR) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap bio therapeutic drugs companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.
This is a summary of current recommendations and price targets for ProQR Therapeutics and Acorda Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation & Earnings
This table compares ProQR Therapeutics and Acorda Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ProQR Therapeutics||N/A||N/A||-$43.27 million||($2.05)||-1.66|
|Acorda Therapeutics||$519.60 million||2.09||-$34.61 million||($1.21)||-19.21|
Acorda Therapeutics has higher revenue and earnings than ProQR Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
31.6% of ProQR Therapeutics shares are owned by institutional investors. 7.9% of Acorda Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk & Volatility
ProQR Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.
This table compares ProQR Therapeutics and Acorda Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Acorda Therapeutics beats ProQR Therapeutics on 7 of the 13 factors compared between the two stocks.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide, for the treatment of Leber’s congenital amaurosis (LCA), and QR-313 for the treatment of dystrophic epidermolysis bullosa (DEB).
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and MS. The Company’s product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
What are top analysts saying about ProQR Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ProQR Therapeutics and related companies.